Trial Profile

A first in human Phase 1 clinical study (RVL-HV02) to evaluate escalating doses of intravenously administered Gemini in healthy individuals

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glycopyranosyl lipid adjuvant (Primary)
Indications Acute kidney injury; Allergic rhinitis; COVID 2019 infections; Influenza A virus H3N2 subtype; Influenza virus infections; Nasal congestion; Non-alcoholic steatohepatitis; Postoperative infections; Renal failure; Respiratory tract infections; SARS-CoV-2 acute respiratory disease
Focus Adverse reactions; First in man

Most Recent Events

24 Sep 2024 Results presented in a Revelation Biosciences Media Release.
09 Aug 2024 According to Revelation Biosciences media release, company completed dosing of its first in human phase 1 clinical study of Gemini.
24 Jun 2024 Results presented in a Revelation Biosciences Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com